What Is Glycosylation? How Sugars Are Attached to Peptides and Proteins

Published October 2026 · Patriot Labs Research Team · ~18 min read

The short answer

Glycosylation is the attachment of a carbohydrate — a sugar or a chain of sugars, called a glycan — to a protein or peptide, producing a glycoprotein. It is one of the most common modifications in biology, built by a set of enzymes rather than copied from a genetic template, and it reshapes how a molecule folds, how long it lasts and how it is recognised.

Because glycosylation is enzyme-built and not templated, it behaves differently from the protein chain it decorates. The amino-acid sequence is read off from DNA and copied faithfully; the glycan is assembled by competing enzymes in the cell’s secretory pathway, so a single site usually carries not one fixed glycan but a spread of related structures. The two main kinds are named for the atom the sugar attaches to: N-linked, joined to the nitrogen of an asparagine side chain, and O-linked, joined to the oxygen of a serine or threonine side chain. The rest of this guide takes those apart in turn.

What glycosylation is, atom by atom

A glycan is a carbohydrate: one sugar (a monosaccharide) or many linked together (an oligosaccharide or polysaccharide). Glycosylation forms a covalent bond — a glycosidic bond — between a sugar and an amino-acid side chain on the protein. The sugar’s reactive carbon (its anomeric carbon) joins to an atom on the side chain, and the point of attachment is what names the whole category.

In N-linked glycosylation the sugar is joined to the amide nitrogen of an asparagine (Asn) side chain — an N-glycosidic bond. In O-linked glycosylation the sugar is joined to the hydroxyl oxygen of a serine (Ser) or threonine (Thr) side chain — an O-glycosidic bond. A handful of rarer forms exist too, such as C-linked mannose on tryptophan and glycans attached through other residues, but N- and O-linked account for the overwhelming majority of protein glycosylation.

The glycans themselves are assembled from a modest alphabet of monosaccharides. In human glycoproteins the recurring building blocks are N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), mannose (Man), galactose (Gal), fucose (Fuc), glucose (Glc) and the sialic acids, of which N-acetylneuraminic acid is the common human form. What makes glycans so much more varied than proteins or nucleic acids is that these sugars can be joined in many ways: at different carbon positions, in two anomeric orientations (α or β), and with branches, so a given set of sugars can be arranged into a large number of distinct structures. That combinatorial richness is why glycosylation adds not just mass but information to a protein.

N-linked vs O-linked: the two main glycosidic links

The two principal forms of glycosylation differ in where the glycan attaches, where in the cell it is built, and whether a consensus sequence governs it. N-linked and O-linked glycosylation are not variations on one reaction; they are run by different enzymes in different compartments and follow different rules.

N-linked glycosylation attaches the glycan to the amide nitrogen of an asparagine, and it is the more regimented of the two. It begins in the endoplasmic reticulum, it is directed by a consensus sequon (Asn–X–Ser/Thr, with X any residue except proline), and every mature N-glycan is built on a shared five-sugar core. O-linked glycosylation, in its common mucin-type form, attaches the glycan to the hydroxyl oxygen of a serine or threonine, is assembled in the Golgi apparatus one sugar at a time, is initiated by a family of enzymes that add N-acetylgalactosamine, and has no universal consensus sequence governing where it lands. The table sets the two side by side.

A separate, chemically distinct O-linked modification — O-GlcNAc — does not fit the mucin-type description at all and is covered in its own section below, because it happens inside the cell rather than in the secretory pathway and behaves like a regulatory switch rather than a structural coat.

How a cell builds an N-glycan: the dolichol pathway

N-linked glycosylation is built in an unusual way: the cell does not add sugars one at a time onto the protein, but pre-assembles a large glycan on a lipid carrier and then transfers the whole block onto the protein in a single step. This is the dolichol pathway, and it is one of the most conserved processes in eukaryotic cell biology.

The glycan is built on the membrane lipid dolichol phosphate, on the face of the endoplasmic reticulum, into a 14-sugar precursor with the composition Glc₃Man₉GlcNAc₂ — three glucoses, nine mannoses and two N-acetylglucosamines. When a protein is threaded into the ER as it is being made, an enzyme complex called the oligosaccharyltransferase (OST), whose catalytic subunit is named STT3, transfers this whole 14-sugar block from the lipid onto an asparagine in a suitable sequon. Because the OST sits at the point where the nascent chain enters the ER, the transfer happens co-translationally — while the protein is still being synthesised.

What follows is extensive remodelling. The three glucoses are trimmed off, and this trimming is read by the cell’s quality-control machinery: the chaperones calnexin and calreticulin recognise the partly trimmed glycan and hold the protein until it has folded correctly, a surveillance system that uses the N-glycan as a folding tag. Mannoses are then removed, and as the protein moves into the Golgi the glycan is rebuilt into one of several mature shapes — high-mannose, hybrid or complex — by adding back sugars such as further GlcNAc, galactose, fucose and sialic acid. The common five-sugar core (Man₃GlcNAc₂) survives all of this, which is why every N-glycan, however elaborate, shares the same root. The mechanism and principles of this pathway were set out in detail in the reviews by Helenius and Aebi and by Schwarz and Aebi.

O-linked glycosylation and the O-GlcNAc switch

O-linked glycosylation is a looser, more varied process than the N-linked pathway, and it comes in two very different styles. The first is the classic mucin-type O-glycosylation that coats secreted and cell-surface proteins. It is built in the Golgi, one sugar at a time, and it begins when one of a large family of enzymes (the polypeptide N-acetylgalactosaminyltransferases) attaches an N-acetylgalactosamine to the hydroxyl of a serine or threonine. From that first GalNAc the chain is extended and branched into a range of core structures. There is no simple consensus sequence that predicts where mucin-type O-glycosylation will occur, which makes it harder to anticipate than the N-linked sequon; it tends to cluster in serine- and threonine-rich stretches, as in the mucins that give the modification its name.

The second style is entirely different. O-GlcNAc is the addition of a single N-acetylglucosamine to serine and threonine residues of proteins in the cytoplasm and nucleus — not in the secretory pathway. Unlike the elaborate glycans of the ER and Golgi, O-GlcNAc is just one sugar, and crucially it is dynamic: it is put on by one enzyme (O-GlcNAc transferase, OGT) and taken off by another (O-GlcNAcase, OGA), cycling on and off much like a phosphate group. Because it is reversible and often competes with phosphorylation for the same residues, O-GlcNAc is understood as a nutrient- and stress-sensitive regulatory mark rather than a structural coat, as described by Hart and colleagues. It is the clearest example that “glycosylation” spans both permanent structural decoration and fast regulatory signalling.

The sequon, and why glycosylation is not template-driven

N-linked glycosylation is governed by a short recognition sequence called the sequon: an asparagine, then any amino acid except proline, then a serine or threonine — written Asn–X–Ser/Thr or N–X–S/T. The oligosaccharyltransferase recognises this pattern and installs the glycan on the asparagine. Proline in the middle position blocks the reaction because it kinks the backbone into a shape the enzyme cannot accommodate.

But the sequon is necessary, not sufficient. Large proteomic surveys — such as the in vivo N-glycoproteome mapping by Zielinska and colleagues — show that many sequons in real proteins are never glycosylated, because the site is buried in the folded structure or otherwise inaccessible when the enzyme passes. The sequence marks where glycosylation can happen; the three-dimensional context decides whether it does.

This points to the deepest difference between glycosylation and the other information-bearing polymers of the cell. DNA is copied from DNA, and protein is translated from messenger RNA, each by faithful template-reading. Glycans have no template. A glycan is the net product of many enzymes competing for the same growing structure, their activity shaped by which enzymes are present, the supply of sugar donors, and how long the protein lingers in each compartment. The consequence is that one protein site does not carry a single defined glycan but a distribution of related ones. The different glycosylated versions of a protein are its glycoforms, and the resulting variability is called microheterogeneity. This is not sloppiness; it is intrinsic to how glycosylation works, and it is why a glycoprotein is described by a profile of glycans rather than a single structure — a point that matters enormously for analysis and for manufacturing.

How common glycosylation is

Glycosylation is one of the most widespread protein modifications known. Analyses of protein sequence databases have long indicated that more than half of all proteins are glycoproteins, and glycosylation is routinely ranked among the most abundant and most structurally complex of all the modifications a protein can carry.

The prevalence is not even across the cell. Glycosylation is concentrated on the proteins that face the outside world — those secreted from the cell or displayed on its surface — because these pass through the ER and Golgi where the glycosylation machinery lives. The result is that essentially every cell is wrapped in a dense layer of glycans, often called the glycocalyx, and much of what one cell “sees” of another is in fact this sugar coat. Proteins that stay inside the cell, in the cytoplasm and nucleus, are glycosylated far less by the elaborate N- and O-linked pathways, but many of them carry the single-sugar O-GlcNAc mark instead. Ajit Varki’s overview of the biological roles of glycans gives a sense of just how central this surface chemistry is to the life of a cell.

Why it matters: folding, stability, recognition and immunity

For a modification that is often invisible in a bare sequence, glycosylation does a remarkable amount of work. Several roles recur across the literature.

The first is folding and quality control. As described above, the N-glycan serves as a tag that the ER’s chaperone system reads to decide whether a protein has folded correctly, so glycosylation is wired directly into the cell’s protein-quality machinery. The second is stability and solubility: a bulky, hydrophilic glycan keeps proteins soluble, shields the surface from aggregation, and physically blocks proteases from reaching the backbone, so glycosylated proteins tend to be more robust and longer-lived. The third is recognition. Glycans are read by a large set of sugar-binding proteins called lectins, and these glycan–lectin interactions underlie cell adhesion, trafficking of cells through tissues, and the docking of many pathogens, which exploit host glycans as entry points. The fourth is immunity: the glycans on a protein help the immune system distinguish self from non-self, shape how antibodies function, and determine whether a surface looks foreign, a theme reviewed by Rudd and colleagues. The broad functional reach of glycosylation across health and disease is surveyed by Ohtsubo and Marth and by Reily and colleagues.

None of this means a glycan does the same thing on every protein. The direction and size of the effect depend on the protein, the site and the specific glycan structures present. What is reliable is the general lesson: the sugar coat is part of the information a protein carries, and changing it changes how the protein folds, lasts and is read.

Glycosylation in protein drugs and glycoengineering

Glycosylation sits at the centre of the biologic-drug industry, because many therapeutic proteins — antibodies, hormones and clotting factors among them — are glycoproteins whose glycans strongly affect how they behave. This is one of the sharpest practical lines between a small synthetic peptide and a large biologic: a glycoprotein generally cannot be made by simple chemical synthesis and must be produced in living cells that can carry out glycosylation, which is a major reason such molecules are manufactured by recombinant expression rather than on a synthesiser. For that distinction, see Recombinant vs Synthetic Peptides and Peptide vs Drug vs Biologic.

Because glycans influence half-life, glycosylation can be engineered deliberately. The clearest example is darbepoetin alfa, an engineered relative of the hormone erythropoietin. Erythropoietin’s circulating lifetime depends heavily on the sialic acid that caps its glycans, so researchers introduced amino-acid substitutions that create two additional N-linked glycosylation sites; the extra, more heavily sialylated glycans slow the molecule’s clearance and give it roughly a three-fold longer serum half-life than the earlier epoetin. The strategy — adding glycosylation to extend half-life — was described by Elliott and colleagues and is a textbook case of glycoengineering. It belongs to the same family of stability strategies as lipidation and PEGylation, which attach a fatty acid or a polymer instead of a sugar; see What Is Lipidation? and What Is PEGylation?, and the overview in Peptide Half-Life Extension.

The flip side of glycans mattering is that they must be controlled. Because glycosylation is heterogeneous and depends on the cell line and the culture conditions, the glycan profile of a therapeutic glycoprotein is treated as a critical quality attribute that has to be characterised and monitored throughout development and production — two batches of the “same” protein can differ meaningfully if their glycosylation differs.

How glycopeptides are made in the laboratory

Putting a defined glycan onto a peptide in the laboratory is far harder than making the bare peptide, and the contrast is instructive. Ordinary research peptides are assembled by solid-phase peptide synthesis (SPPS), in which the chain is built one protected amino acid at a time on a resin bead — the method is covered in What Is Solid-Phase Peptide Synthesis?. A plain peptide carries no sugars; to make a glycopeptide, the sugar has to be built in.

The usual chemical route is to prepare a glycosylated amino-acid building block — an amino acid that already carries its sugar, correctly protected — and to couple that block into the chain during SPPS like any other residue. The difficulty is that these building blocks are laborious to synthesise, the glycosidic bonds are sensitive to the acids and bases used in peptide chemistry, and a single defined glycan has to be assembled with exactly the right linkages and stereochemistry. For larger, homogeneous glycoproteins, chemists turn to convergent strategies that join a synthetic glycan to a synthetic or expressed peptide, often with the help of enzymes — a chemoenzymatic approach. The refined toolbox for this kind of chemical assembly of N-glycoproteins is reviewed by Unverzagt and Kajihara.

The reason this matters for understanding glycosylation is that it throws the biology into relief. A cell makes glycoproteins routinely but heterogeneously, producing mixtures of glycoforms; a chemist can make a single, defined glycoform but only with great effort. Neither is simply “better” — they are suited to different ends, the cell for scale and the chemist for homogeneity.

How glycosylation is detected and measured

Glycosylation is studied at several levels of detail, from a quick yes/no to a full site-by-site map. The simplest clue appears on a gel: because a glycoprotein carries a spread of glycoforms of slightly different mass, it runs heavier than its bare sequence would predict and as a broad, fuzzy band rather than a sharp one. That smear is often the first sign that a protein is glycosylated, and the band sharpens if the glycans are removed enzymatically.

To characterise the glycans themselves, the standard workflow releases them from the protein and analyses them separately. The enzyme PNGase F cleaves N-linked glycans off the protein; the freed glycans are then tagged with a fluorescent label (such as 2-AB or a rapid mass-spectrometry-friendly tag) and separated by HILIC-HPLC or UPLC, with identities assigned by mass spectrometry. To determine not just which glycans are present but which glycan sits on which site, intact glycopeptides are analysed directly by liquid chromatography–tandem mass spectrometry, the field known as glycoproteomics. Lectins — proteins that bind particular sugars — provide another route, used to detect, stain or enrich glycoproteins by the sugars they carry.

Across all of these, mass spectrometry is the backbone, because glycosylation’s signature is a defined increase in mass whose size reports the glycan’s composition. This is where quality documentation meets the science: an analytical certificate reports a molecule’s measured mass and purity, and for a glycosylated molecule that mass reflects the glycans present. Patriot Labs reports each lot’s identity and purity from an independent US laboratory by HPLC and mass spectrometry, with the certificate of analysis available on the product page; for how to read those documents, see Understanding Peptide COA Testing.

When glycosylation goes wrong: disease

Because glycosylation touches folding, stability, recognition and immunity, disruptions to it have consequences, and the study of those consequences is a large field in its own right. Inherited defects in the glycosylation machinery cause a group of rare conditions known as the congenital disorders of glycosylation, in which a faulty enzyme in the N- or O-linked pathway produces incorrectly built glycans with wide-ranging effects, reflecting how many systems depend on correct glycosylation.

Altered glycosylation is also a recurring feature of other disease states. Changes in the glycans displayed on cell surfaces accompany many cancers, where the sugar coat shifts in characteristic ways, and glycosylation changes are studied across immune, inflammatory and metabolic conditions as well. The reviews by Ohtsubo and Marth and by Reily and colleagues survey this territory, treating glycosylation as a thread that runs through both normal physiology and disease. For the purposes of this guide, the key point is descriptive: glycosylation is important enough that getting it wrong matters, which is precisely why it is studied so intensively as a piece of fundamental biology.

What this guide does not establish

This guide is an explanation of a chemical and biological modification. It is not a claim about any product’s effects, and several boundaries are worth stating plainly.

• Nothing here describes any use in a person or animal. Biology is described to explain how proteins are glycosylated and why the modification changes a molecule’s properties, not to suggest that any compound should be administered or that it produces any effect in a living subject.
• Glycosylation is a structural fact, not a benefit. That a glycan can influence folding, stability, recognition or half-life in the published research describes a molecule’s chemistry and biology; it is not a statement that any research compound is safe, effective, or suitable for any purpose.
• Whether a given peptide is glycosylated depends on the specific molecule. Most short synthetic peptides are not glycosylated at all. The examples here are drawn from the scientific literature on proteins and glycoproteins; they do not indicate the glycosylation state of any particular product, which is defined by that product’s own specification and certificate of analysis.
• Nothing here describes where Patriot Labs’ peptides are synthesized. Patriot Labs is a first-responder-owned, US-based company, and the only quality facts used here are that every lot is tested by an independent US laboratory by HPLC and mass spectrometry, with the COA available on the product page.

Frequently asked questions

What is glycosylation?

Glycosylation is the attachment of a carbohydrate — a sugar or a chain of sugars, called a glycan — to a protein or peptide, producing a glycoprotein. It is one of the most common and most structurally diverse modifications in biology, carried out by a large set of enzymes rather than copied from a genetic template. Because it is enzyme-built and not templated, the same protein site usually ends up carrying a range of related glycans rather than a single fixed one. The two main forms are N-linked glycosylation, where the glycan is attached to the nitrogen of an asparagine side chain, and O-linked glycosylation, where it is attached to the oxygen of a serine or threonine side chain.

What is the difference between N-linked and O-linked glycosylation?

They differ in the atom the glycan attaches to and the residue it attaches to. N-linked glycosylation joins the glycan to the amide nitrogen of an asparagine (Asn) side chain, within the consensus sequon Asn–X–Ser/Thr where X is any residue except proline; it begins in the endoplasmic reticulum, and all N-glycans share a common five-sugar core. O-linked glycosylation joins the glycan to the hydroxyl oxygen of a serine or threonine (and less commonly tyrosine or hydroxyproline); the best-known mucin type is built in the Golgi, starts with N-acetylgalactosamine, and has no universal consensus sequence. A distinct O-linked form, O-GlcNAc, adds a single N-acetylglucosamine to nuclear and cytoplasmic proteins as a dynamic regulatory mark.

Where in the cell does glycosylation happen?

Most protein glycosylation happens along the secretory pathway, in the endoplasmic reticulum (ER) and the Golgi apparatus. N-linked glycosylation begins in the ER: a pre-assembled 14-sugar glycan is transferred onto the protein as it is being made, then trimmed and rebuilt as the protein moves into and through the Golgi. Mucin-type O-linked glycosylation is added later, in the Golgi. The exception is O-GlcNAc, which is added in the cytoplasm and nucleus by a different enzyme and is not part of the secretory pathway.

What is the N-X-S/T sequon in glycosylation?

The N-X-S/T sequon is the short consensus sequence that marks most sites of N-linked glycosylation: an asparagine (N), followed by any amino acid except proline (X), followed by a serine or threonine (S/T). The enzyme that installs the glycan, oligosaccharyltransferase, recognises this three-residue pattern. The sequon is necessary but not sufficient — many sequons in real proteins are never glycosylated because they are buried, folded away, or otherwise inaccessible when the enzyme passes — which is why the sequence alone predicts a possible site rather than a guaranteed one.

Is glycosylation the same on every copy of a protein?

No. Unlike the amino-acid sequence, which is copied faithfully from DNA, glycosylation is not template-driven: it is the net result of many competing enzymes acting in the ER and Golgi, so a single glycosylation site on a protein typically ends up carrying a distribution of related but different glycans. The various glycosylated versions of one protein are called glycoforms, and the site-to-site and molecule-to-molecule variation is called microheterogeneity. This is why glycoproteins are characterised as a profile of glycan structures rather than a single sequence, and why glycosylation is a defining analytical challenge for glycoproteins.

How common is glycosylation?

Very common. Analyses of protein databases have long suggested that more than half of all proteins are glycosylated, and glycosylation is routinely described as one of the most abundant and most complex protein modifications. It is especially prevalent among secreted and cell-surface proteins — the proteins that face the outside world — where the glycan coat is central to how cells recognise one another and how the immune system reads a surface. Nuclear and cytoplasmic proteins are more often modified by the single-sugar O-GlcNAc mark.

Why does glycosylation matter for a protein's stability and half-life?

Glycans add bulk and, when capped with sialic acid, negative charge, and both change how long a protein lasts in circulation. A glycan shields the protein surface from proteases and can slow clearance through the kidney and through sugar-recognising receptors in the liver. This is the basis of glycoengineering: darbepoetin alfa, an engineered version of erythropoietin, was given amino-acid substitutions that add two extra N-linked glycan chains, raising its sialic-acid content and giving it roughly a three-fold longer serum half-life than the earlier epoetin. The size and direction of such effects depend on the specific protein and the specific glycans.

Are research peptides glycosylated?

Most short synthetic research peptides are not glycosylated. Glycosylation is overwhelmingly a feature of larger proteins and glycoproteins built by the cell's secretory machinery, and the short peptides made by solid-phase chemical synthesis are generally plain, unglycosylated sequences unless a glycan is deliberately built in. Adding a defined glycan to a synthetic peptide is possible but demanding, usually requiring pre-made glycosylated amino-acid building blocks or chemoenzymatic assembly. Whether any particular peptide carries a glycan is defined by that molecule's own structure and specification, not assumed.

How is glycosylation detected and measured?

Glycosylation is studied at several levels. A quick first clue is that glycoproteins run heavier and as broad, fuzzy bands on a gel because of their glycan heterogeneity. To characterise the glycans, an enzyme such as PNGase F is used to release N-linked glycans from the protein; the freed glycans are then labelled with a fluorescent tag and separated by HILIC-HPLC or UPLC and identified by mass spectrometry. To map which glycan sits on which site, intact glycopeptides are analysed directly by liquid chromatography–tandem mass spectrometry (glycoproteomics). Lectins, which bind specific sugars, are also used to detect and enrich glycoproteins.

References

1. Varki, A. (2017). Biological roles of glycans. Glycobiology, 27(1), 3–49. doi:10.1093/glycob/cww086
2. Moremen, K. W., Tiemeyer, M., & Nairn, A. V. (2012). Vertebrate protein glycosylation: diversity, synthesis and function. Nature Reviews Molecular Cell Biology, 13. doi:10.1038/nrm3383
3. Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019). Glycosylation in health and disease. Nature Reviews Nephrology, 15, 346–366. doi:10.1038/s41581-019-0129-4
4. Helenius, A., & Aebi, M. (2001). Intracellular Functions of N-Linked Glycans. Science, 291(5512), 2364–2369. doi:10.1126/science.291.5512.2364
5. Breitling, J., & Aebi, M. (2013). N-Linked Protein Glycosylation in the Endoplasmic Reticulum. Cold Spring Harbor Perspectives in Biology, 5(8). doi:10.1101/cshperspect.a013359
6. Schwarz, F., & Aebi, M. (2011). Mechanisms and principles of N-linked protein glycosylation. Current Opinion in Structural Biology, 21(5). doi:10.1016/j.sbi.2011.08.005
7. Spiro, R. G. (2002). Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology, 12(4), 43R–56R. doi:10.1093/glycob/12.4.43R
8. Apweiler, R., et al. (1999). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochimica et Biophysica Acta (BBA) – General Subjects, 1473(1). doi:10.1016/S0304-4165(99)00165-8
9. Hart, G. W., Housley, M. P., & Slawson, C. (2007). Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. doi:10.1038/nature05815
10. Ohtsubo, K., & Marth, J. D. (2006). Glycosylation in Cellular Mechanisms of Health and Disease. Cell, 126(5), 855–867. doi:10.1016/j.cell.2006.08.019
11. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001). Glycosylation and the Immune System. Science, 291(5512), 2370–2376. doi:10.1126/science.291.5512.2370
12. Dwek, R. A. (1996). Glycobiology: Toward Understanding the Function of Sugars. Chemical Reviews, 96(2). doi:10.1021/cr940283b
13. Zielinska, D. F., Gnad, F., Wiśniewski, J. R., & Mann, M. (2010). Precision Mapping of an In Vivo N-Glycoproteome Reveals Rigid Topological and Sequence Constraints. Cell, 141(5), 897–907. doi:10.1016/j.cell.2010.04.012
14. Elliott, S., et al. (2003). Enhancement of therapeutic protein in vivo activities through glycoengineering. Nature Biotechnology, 21(4), 414–421. doi:10.1038/nbt799
15. Unverzagt, C., & Kajihara, Y. (2013). Chemical assembly of N-glycoproteins: a refined toolbox to address a ubiquitous posttranslational modification. Chemical Society Reviews, 42. doi:10.1039/c3cs35485g
16. Darbepoetin alfa. Wikipedia. https://en.wikipedia.org/wiki/Darbepoetin_alfa
17. Released Glycan Analysis using PNGase F. Genovis. https://www.genovis.com/application/released-glycan-analysis-using-pngase-f/
18. N-Linked vs O-Linked Glycosylation: Structure, Function and Disease Links. MetwareBio. https://www.metwarebio.com/n-linked-vs-o-linked-glycosylation-structure-function-disease/

For related chemistry, see What Is Acetylation? and What Is Amidation? for the terminal caps that modify a chain, What Is Lipidation? and Peptide Half-Life Extension for other ways a molecule’s circulating lifetime is extended, Recombinant vs Synthetic Peptides for why glycoproteins are grown in cells rather than synthesised, and Understanding Peptide COA Testing for how a modification is confirmed by mass on a certificate of analysis.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes glycosylation as a chemical and biological modification in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the composition or modification state of any specific product.